How it all started
In 2013 OKIDS was launched to limit the off-label use of drugs and the associated threats to children and to give kids equal access to tested and safe medicinal products.
On May 17th, 2013 the OKIDS kick-off event took place in ballroom of the Federal Ministry of Health under the moderation of Prim. Univ.-Prof. Dr. Reinhold Kerbl, President of the ÖGKJ.
Watch the informative and emotional presentation of the network here as recorded May 17th, 2013.
Welcoming
Univ.-Prof. Dr. Ruth Ladenstein, Managing Director OKIDS, Head of the coordination center for clinical studies and statistics at St. Anna Children's Cancer Research
Opening
Alois Stöger, Minister for Health
OKIDS – The pediatric drug research network for Austria takes off
Univ.-Prof. Dr. Ruth Ladenstein, Managing Director OKIDS, Head of the coordination center for clinical studies and statistics at St. Anna Children's Cancer Research
The role and importance of industry at OKIDS
Dr. Jan Oliver Huber, Pharmig Secretary General
European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)
Univ.-Prof. Dr. Irmgard Eichler, Scientific Administrator, Paediatric Medicine, European Medicines Agency
Paediatric Therapeutic Needs and the OKIDS Expert panel
Univ.-Prof. Dr. Christoph Male, OKIDS, Senior physician at the Univ. Clinic for Pediatrics, Vienna
National hub for industrial studies in the OKIDS network
PD Dr.med. Florian B. Lagler, OKIDS, Manager at the Clinical Research Center Salzburg GmbH
The importance of OKIDS from the point of view of the ÖGKJ
Prim. Univ.-Prof. Dr. Reinhold Kerbl, Chairman ÖGKJ, Head of the Department for Children and Adolescents at the LKH Leoben
Why a children's research network? The public health view
Univ.-Prof. Dr. Marcus Müllner, Head of the AGES Medical Market Supervision division